Influence of Inflammatory and Oxidative Stress Pathways on Longitudinal Symptom Experiences in Children With Leukemia
AuthorHockenberry, Marilyn J
Scheurer, Michael E
Hooke, Mary C
AffiliationUniv Arizona, Coll Nursing
longitudinal parallel process
oxidative stress biomarker
MetadataShow full item record
PublisherSAGE PUBLICATIONS INC
CitationHockenberry, M. J., Pan, W., Scheurer, M. E., Hooke, M. C., Taylor, O., Koerner, K., … Moore, I. (2019). Influence of Inflammatory and Oxidative Stress Pathways on Longitudinal Symptom Experiences in Children With Leukemia. Biological Research For Nursing, 21(5), 458–465. https://doi.org/10.1177/1099800419863160
JournalBIOLOGICAL RESEARCH FOR NURSING
Rights© The Author(s) 2019
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractPurpose: The purpose of this study was to explore the influence of oxidative stress (F2-isoprostanes) and inflammatory (interleukin [IL]-8) biomarkers on symptom trajectories during the first 18 months of childhood leukemia treatment. Method: A repeated-measures design was used to evaluate symptoms experienced by 218 children during treatment. A symptom cluster (fatigue, pain, and nausea) was explored over four time periods: initiation of post-induction therapy, 4 and 8 months into post-induction therapy, and the beginning of maintenance therapy (12 months postinduction). F2-isoprostanes and IL-8 were evaluated in cerebrospinal fluid (CSF) samples collected at baseline (diagnosis) and then at the four time periods. The longitudinal relationships of these biomarkers with the symptom cluster were examined using the longitudinal parallel process. Results: Pain and fatigue levels were highest during the post-induction phases of treatment and decreased slightly during maintenance therapy, while nausea scores were relatively stable. Even in the later phases of treatment, children continued to experience symptoms. CSF levels of the biomarkers increased during the post-induction phases of treatment. Early increases in the biomarkers were associated with more severe symptoms during the same period; patients who had increased biomarkers over time also experienced more severe symptoms over time. Conclusions: Findings reveal that children experienced symptoms throughout the course of leukemia treatment and support hypothesized longitudinal relationships of oxidative stress and inflammatory biomarkers with symptom severity. Activation of the biomarker pathways during treatment may explain underlying mechanisms of symptom experiences and identify which children are at risk for severe symptoms.
VersionFinal accepted manuscript
SponsorsNational Institutes of Health [R01CA1693398]
- The influence of oxidative stress on symptom occurrence, severity, and distress during childhood leukemia treatment.
- Authors: Hockenberry MJ, Taylor OA, Pasvogel A, Rodgers C, McCarthy K, Gundy P, Montgomery DW, Ribbeck P, Scheurer ME, Moore IM
- Issue date: 2014 Jul 1
- Influence of Nitrosative Stress on Fatigue During Childhood Leukemia Treatment.
- Authors: Hockenberry MJ, Moore IMK, Scheurer ME, Hooke MC, Taylor OA, Koerner KM, Gundy PM, Pan W
- Issue date: 2018 Jul
- Physical Activity, the Childhood Cancer Symptom Cluster-Leukemia, and Cognitive Function: A Longitudinal Mediation Analysis.
- Authors: Hooke MC, Rodgers C, Taylor O, Koerner KM, Mitby P, Moore I, Scheurer ME, Hockenberry MJ, Pan W
- Issue date: 2018 Nov/Dec
- F2-isoprostanes: a measure of oxidative stress in children receiving treatment for leukemia.
- Authors: Hockenberry MJ, Taylor OA, Gundy PM, Ross AK, Pasvogel A, Montgomery D, Ribbeck P, McCarthy K, Moore I
- Issue date: 2014 Jul
- The Longitudinal Parallel Process Analysis of Biomarkers of Oxidative Stress, Symptom Clusters, and Cognitive Function in Children With Leukemia.
- Authors: Hooke MC, Hatch D, Hockenberry MJ, Whitman S, Moore I, Montgomery D, Marano K, Mitby P, Scheurer ME, Taylor O, Pan W
- Issue date: 2020 Mar 6